Professor Dato' Sri Dr. Mike K.S. Chan is a pioneer of Cellular and Cell Membrane Therapy in Europe and Asia since the early 1980's. He founded one of the world's largest researchers of Bio-Molecular Medicine based in Switzerland and Germany with a global presence in almost eighty countries. He has conducted more than 1,000 lectures, seminars, and symposiums worldwide in the fields of antiaging, cell regeneration, regenerative medicine, and stem-cell therapies. Prof. Dato' Sri Dr. Michelle Wong Bi Fah, ND, PhD, is a scientist actively involved in research and development (R&D) work on stem cells focusing on Foetal Precursor Stem-Cell Therapy. She is the Co-Founder/Technical Advisor and Researcher of FCTI Inc. Her primary role is envisioning and devising a strategic roadmap for the organization's growth, especially in today's rapidly evolving business ecosystem. A prominent speaker, Dr. Wong presents at educational programs and global conferences on cell therapy and biological medicine for physicians and healthcare practitioners worldwide. Dr. Patricia Pan is a researcher specializing in the fields of animal stem cells, clinical microbiology, environmental microbiology, and medical biotechnology and immunology. She holds a PhD in Biotechnology focusing on natural immunomodulators which augment the immune system to protect against infections. Dr. Pan lectured and trained medical laboratory technology students as a tutor, lecturer, and Head of School in the field of Medical Laboratory Technology. Lecture topics included clinical microbiology, immunology and serology, immunohematology and clinical parasitology. Mentored students achieved successful careers as medical laboratory technologists. She currently works as the Head of Research focusing on developing new research projects including protocol design, analysis, and results interpretation. She is also a prolific contributing writer of review and research articles in the field of regenerative medicine including stem cells biology, its mechanisms, and medical application. Dr. Pan currently monitors the progress of preclinical animal studies and clinical trials for Investigational New Drug (IND) submission.